← FDA DRUG APPROVALS

FDA NDA · NDA020398

PROPULSID

Sponsor: JANSSEN PHARMS

APPLICATION
NDA020398
TYPE
NDA
ORIGINAL APPROVAL
1995-09-15
LATEST ACTION
2000-03-06
ROUTE
ORAL
DOSAGE FORM
SUSPENSION
MARKETING STATUS
Discontinued

Products

PROPULSIDDiscontinued
CISAPRIDE MONOHYDRATE EQ 1MG BASE/ML · SUSPENSION · ORAL

Approval history

2000-03-06Labeling · Supplement 22 · standardReviewAP
2000-03-06Labeling · Supplement 20 · standardReviewAP
1999-11-10Manufacturing (CMC) · Supplement 19 · standardAP
1999-03-24Manufacturing (CMC) · Supplement 18 · standardAP
1999-02-08Manufacturing (CMC) · Supplement 17 · standardAP
1999-01-12Manufacturing (CMC) · Supplement 16 · standardAP
1998-09-22Manufacturing (CMC) · Supplement 13 · standardAP
1998-08-17Labeling · Supplement 15 · standardAP
1998-08-06Manufacturing (CMC) · Supplement 10 · standardAP
1998-07-31Labeling · Supplement 14 · standardAP
1998-06-26Manufacturing (CMC) · Supplement 11 · standardAP
1997-11-07Labeling · Supplement 8 · standardAP
1997-10-28Manufacturing (CMC) · Supplement 6 · standardAP
1997-01-31Manufacturing (CMC) · Supplement 4 · standardAP
1995-12-11Labeling · Supplement 2 · standardAP
1995-11-01Manufacturing (CMC) · Supplement 1 · standardAP
1995-09-15Type 3 - New Dosage Form · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →